Cardiovascular Disease

Daily glucocorticoid doses of 5 mg or more during the preceding 6 or 12 months is associated with an increased risk for cardiovascular events in steroid-naïve patients with rheumatoid arthritis, according to data.

Individuals with mental disorders, particularly those with schizophrenia, received less screening and lower-quality treatment for cardiovascular disease, according to results of a systematic review and meta-analysis.

The SGLT2 inhibitor ertugliflozin shows promise for preserving kidney function in patients with type 2 diabetes and atherosclerotic cardiovascular disease, results of a placebo-controlled trial suggested.

Volume reduction in CV diagnostic procedures at the beginning of the COVID-19 pandemic.

Sudden cardiac death in people with HIV vs. those without.

The ADAPTABLE trial, presented and published in May, was notable in two ways: It provided answers on aspirin dosage for patients needing secondary CVD prevention and it showed a large-scale pragmatic trial could work.

For this issue, Cardiology Today spoke with Editorial Board Member Susan Cheng, MD, MPH, MMSc. She is associate professor of medicine and the Erika J. Glazer Chair in Cardiovascular Women’s Health and Population Science, program director of the Center for Research in Women’s Health and Sex Differences, director of cardiovascular population sciences and director of public health research at Smidt Heart Institute, Cedars-Sinai.

Following kidney transplant, patients with Fabry disease had higher mortality rates than those without the disease. However, among patients on dialysis, those with Fabry disease had better mortality rates than patients without the disease.

Firefighters who have a higher BMI and are older are more likely to have a higher prevalence of cardiovascular disease risk factors, according to a study published in Obesity.

Pravastatin compared with placebo did not reduce incidence of delivery with preeclampsia among pregnant women at high risk, according to findings published in Circulation.